Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers for response to biologic therapies in inflammatory bowel disease
2018-002925-47Phase 4Active
- Sponsor
- Fundación de Investigación Biomédica del Hospital Universitario de La Princesa
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adalimumab, infliximab, golimumab, ustekinumab and vedolizumab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (5 arms), sponsored by Fundación de Investigación Biomédica del Hospital Universitario de La Princesa. Primary endpoint: Endoscopic response. Started Nov 2018; status: active.
02
Drugs
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2018-002925-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002925-47.